X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs CIPLA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD CIPLA STRIDES SHASUN LTD/
CIPLA
 
P/E (TTM) x 44.0 40.6 108.3% View Chart
P/BV x 1.1 3.7 29.3% View Chart
Dividend Yield % 0.9 0.5 199.6%  

Financials

 STRIDES SHASUN LTD   CIPLA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
CIPLA
Mar-18
STRIDES SHASUN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,275663 192.3%   
Low Rs918479 191.6%   
Sales per share (Unadj.) Rs389.6189.0 206.1%  
Earnings per share (Unadj.) Rs28.017.6 159.0%  
Cash flow per share (Unadj.) Rs48.934.0 143.7%  
Dividends per share (Unadj.) Rs4.503.00 150.0%  
Dividend yield (eoy) %0.40.5 78.1%  
Book value per share (Unadj.) Rs303.1176.7 171.5%  
Shares outstanding (eoy) m89.42805.12 11.1%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.83.0 93.2%   
Avg P/E ratio x39.232.5 120.8%  
P/CF ratio (eoy) x22.416.8 133.6%  
Price / Book Value ratio x3.63.2 112.0%  
Dividend payout %16.117.1 94.4%   
Avg Mkt Cap Rs m98,036459,724 21.3%   
No. of employees `0005.823.6 24.6%   
Total wages/salary Rs m5,88126,901 21.9%   
Avg. sales/employee Rs Th6,005.96,446.1 93.2%   
Avg. wages/employee Rs Th1,014.01,139.4 89.0%   
Avg. net profit/employee Rs Th431.2600.0 71.9%   
INCOME DATA
Net Sales Rs m34,834152,193 22.9%  
Other income Rs m1,6863,577 47.1%   
Total revenues Rs m36,520155,769 23.4%   
Gross profit Rs m6,42828,264 22.7%  
Depreciation Rs m1,87213,228 14.1%   
Interest Rs m2,2691,142 198.7%   
Profit before tax Rs m3,97317,470 22.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m4-28 -12.9%   
Extraordinary Inc (Exp) Rs m-1,006-775 129.7%   
Tax Rs m4702,501 18.8%   
Profit after tax Rs m2,50114,166 17.7%  
Gross profit margin %18.518.6 99.4%  
Effective tax rate %11.814.3 82.6%   
Net profit margin %7.29.3 77.1%  
BALANCE SHEET DATA
Current assets Rs m38,165108,141 35.3%   
Current liabilities Rs m30,40238,322 79.3%   
Net working cap to sales %22.345.9 48.6%  
Current ratio x1.32.8 44.5%  
Inventory Days Days7797 79.7%  
Debtors Days Days10474 140.4%  
Net fixed assets Rs m37,639109,411 34.4%   
Share capital Rs m8941,610 55.5%   
"Free" reserves Rs m26,210140,682 18.6%   
Net worth Rs m27,105142,292 19.0%   
Long term debt Rs m16,37736,621 44.7%   
Total assets Rs m81,168228,606 35.5%  
Interest coverage x2.816.3 16.9%   
Debt to equity ratio x0.60.3 234.8%  
Sales to assets ratio x0.40.7 64.5%   
Return on assets %5.96.7 87.8%  
Return on equity %9.210.0 92.7%  
Return on capital %12.110.0 121.1%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46551,691 26.0%   
Fx outflow Rs m4,07621,033 19.4%   
Net fx Rs m9,38930,658 30.6%   
CASH FLOW
From Operations Rs m2,88114,628 19.7%  
From Investments Rs m-7,051-8,540 82.6%  
From Financial Activity Rs m3,382-3,855 -87.7%  
Net Cashflow Rs m-7882,431 -32.4%  

Share Holding

Indian Promoters % 27.7 16.0 173.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 37.8 12.2 309.8%  
FIIs % 8.6 23.7 36.3%  
ADR/GDR % 0.0 1.1 -  
Free float % 25.9 26.2 98.9%  
Shareholders   56,241 161,166 34.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - BIOCON LTD COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS